Chronic venous disease;Patologia venosa cronica

Minerva Cardioangiologica

Volumn 55, Issue 4, 2007, Pages 459-476

  Bergan, J J ^a,g   Schmid Schonbein G W ^b   Coleridge Smith, P D ^c   Nicolaides, A N ^d   Boisseau, M R ^e   Eklof, B ^f  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d UNIVERSITY OF CYPRUS   (Cyprus)

^e UNIVERSITÉ DE BORDEAUX   (France)

^f LUND UNIVERSITY   (Sweden)

^g NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHRONIC DISEASE; HUMAN; INFLAMMATION; QUALITY OF LIFE; REVIEW; SHEAR STRESS; SKIN BLOOD VESSEL; SYMPTOM; VEIN DISEASE; VENOUS PRESSURE;

EID: 35948994214     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Porter JM, Moneta GL. Reporting standards in venous disease: an update. J Vasc Surg 1995;21:635-45.
2. Eklof B, Rutherford RB, Bergan JJ, et al. Revision of the CEAP classification for chronic venous disorders: consensus statement. J Vasc Surg 2004;40:1248-52.
3. Evans CJ, Fowkes FGR, Ruckley CV, Lee AJ. Prevalence of varicose veins and chronic venous insufficiency in men and women in the general population: Edinburgh Vein Study. J Epidemiol Community Health 1999;53:149-53.
4. Kurz X, Kahn SR, Abenhaim L, et al. Chronic venous disorders of the leg: epidemiology, outcomes, diagnosis and management: summary of an evidence-based report of the VEINES task force. Int Angiol 1999;18:83-102.
5. Moffatt CJ, Franks PJ, Doherty DC, Martin R, Blewett R, Ross F. Prevalence of leg ulceration in a London population. QJM 2004;97:431-7.
6. Labropoulos N. Hemodynamic changes according to the CEAP classification. Phlebolymphology 2003;40:130-6.
7. Brand FN, Dannenberg AL, Abbott RD, Kannel WB. The epidemiology of varicose veins: the Framingham Study. Am J Prev Med 1988;4:96-101.
8. Lee AJ, Evans CJ, Allan PL, Ruckley CV, Fowkes FG. Lifestyle factors and the risk of varicose veins: Edinburgh Vein Study. J Clin Epidemiol 2003;56:171-9.
9. Criqui MH, Jamosmos M, Fronek A et al. Chronic venous disease in an ethnically diverse population: the San Diego Population Study. Am J Epidemiol 2003;158:448-56.
10. Fowkes FG, Lee AJ, Evans CJ, Allan PL, Bradbury AW, Ruckley CV. Lifestyle risk factors for lower limb venous reflux in the general population: Edinburgh Vein Saidy. Int J Epidemiol 2001;30:846-52.
11. Laurikka JO, Sisto T, Tarkka MR, Auvinen O, Hakama M. Risk indicators for varicose veins in forty- to sixty-year-olds in the Tampere varicose vein study. World J Surg 2002;26:648-51.
12. Chiesa R, Marone EM, Limoni C, Volonte M, Schaefer E, Petrini O. Demographic factors and their relationship with the presence of CVI signs in Italy: the 24-cities cohort study. Eur J Vasc Endovasc Surg 2005;30:674-80.
13. Callam MJ, Harper DR, Dale JJ, Ruckley CV. Chronic ulcer of the leg: clinical history. Br Med J (Clin Res Ed) 1987;294: 1389-91.
14. McGuckin M, Waterman R, Brooks J, et al. Validation of venous leg ulcer guidelines in the United States and United Kingdom. Am J Surg 2002;183:132-7.
15. Ruckley CV. Socioeconomic impact of chronic venous insufficiency and leg ulcers. Angiology 1997;48:67-9.
16. Van den Oever R, Hepp B, Debbaut B, Simon I. Socioeconomic impact of chronic venous insufficiency: an underestimated public health problem. Int Angiol 1998; 17:161-7.
17. Carpentier PH, Cornu-Thénard A, Uhl J-F, Partsch H, Antignani PL. Appraisal of the information content of the C classes of CEAP clinical classification of chronic venous disorders: a multicenter evaluation of 872 patients. J Vasc Surg 2003;37:827-33.
18. Kahn SR, M'lan CE, Lamping DL, Kurz X, Bérard A, Abenhaim LA. Relationship between clinical classification of chronic venous disease and patient-reported quality of life: results from an international cohort study. J Vasc Surg 2004;39: 823-8.
19. van Korlaar I, Vossen C, Rosendaal F, Cameron L, Bovill E, Kaptein A. Quality of life in venous disease. Thromb Haemost 2003;90:27-35.
20. Nemeth KA, Harrison MB, Graham ID, Burke S. Understanding venous leg ulcer pain: results of a longitudinal study. Ostomy Wound Manage 2004;50:34-46.
21. Franks PJ, Moffatt CJ. Health related quality of life in patients with venous ulceration: use of the Nottingham health profile. Qual Life Res 2001;10:693-700.
22. Kaplan RM, Criqui MH, Denenberg JO, Bergan J, Fronek A. Quality of life in patients with chronic venous disease: San Diego Population Study. J Vasc Surg 2003; 37:1047-53.
23. Andreozzi GM, Cordova RM, Scomparin A, Martini R, D'Eri A, Andreozzi F. Quality of life in chronic venous insufficiency: an Italian pilot study of the Tri-veneto Region. Int Angiol 2005;24:272-7.
24. Kistner RL, Eklof B, Masuda EM. Diagnosis of chronic-venous disease of the lower extremities: the "CEAP" classification. Mayo Clin Proc 1996;71:338-45.
25. Tassiopoulos AK, Golts E, Oh DS, Labropoulos N. Current concepts in chronic venous ulceration. Eur J Vasc Endovasc Surg 2000;20:227-32.
26. Coleridge Smith PD. The microcirculation in venous hypertension. Vasc Med 1997;2:203-13.
27. Van Cleef JF, Hugentobler JP, Desvaux P, Griton P, Cloarec M. Étude endos-co-pique des reflux valvulaires saphéniens. J Mal Vasc 1992;17:Suppl B:113-6.
28. Sales CM, Rosenthal D, Petrillo KA, et al. The valvular apparatus in venous insufficiency: a problem of quantity? Ann Vasc Surg 1998;12:153-5.
29. Ono T, Bergan JJ, Schmid-Schönbein GW, Takase S. Monocyte infiltration into venous valves. J Vasc Surg 1998;27:158-66.
30. Takase S, Bergan JJ, Schmid-Schönbein GW. Expression of adhesion molecules and cytokines on saphenous veins in chronic venous insufficiency. Ann Vasc Surg 2000;14:427-35.
31. Travers JP, Brookes CE, Evans J, et al. Assessment of wall structure and composition of varicose veins with reference to collagen, elastin and smooth muscle content. Eur J Vasc Endovasc Surg 1996;11:230-7.
32. Porto LC, Ferreira MA, Costa AM, da Silveira PR. Immunolabeling of type IV collagen, laminin, and alpha-smooth muscle actin cells in the intima of normal and varicose saphenous veins. Angiology 1998; 49:391-8.
33. Wali MA, Eid RA. Changes of elastic and collagen fibers in varicose veins. Int Angiol 2002;21:337-43.
34. Sansilvestri-Morel P, Rupin A, Badier-Commander C, et al. Imbalance in the synthesis of collagen type I and collagen type III in smooth muscle cells derived from human varicose veins. J Vasc Res 2001;38:560-8.
35. Jacob MP, Badier-Commander C, Fontaine V, Benazzoug Y, Feldman L, Michel JB. Extracellular matrix remodeling in the vascular wall. Pathol Biol (Paris) 2001;49: 326-32.
36. Lees M, Taylor DJ, Woolley DE. Mast cell proteinases activate precursor forms of collagenase and stromelysin, but not of gelatinases A and B. Eur J Biochem 1994; 223:171-7.
37. Johnson JL, Jackson CL, Angelini GD, George SJ. Activation of matrix-degrading metalloproteinases by mast cell proteases in atherosclerotic plaques. Arterioscler Thromb Vasc Biol 1998;18:1707-15.
38. Badier-Commander C, Verbeuren T, Lebard C, Michel J-B, Jacob M-P. Increased TIMP/MMP ratio in varicose veins: a possible explanation for extracellular matrix accumulation. J Pathol 2000;192:105-12.
39. Badier-Commander C, Couvelard A, Henin D, Verbeuren T, Michel J-B, Jacob M-P. Smooth muscle cell modulation and cytokine overproduction in varicose veins: an in situ study. J Pathol 2001;193:398-407.
40. Overall CM, Wrana JL, Sodek J. Transcriptional and post-transcriptional regulation of 72-kD gelatinase/type IV collagenase by transforming growth factor-β1 in human fibroblasts: comparisons with collagenase and tissue inhibitor of matrix metalloproteinase gene expression. J Biol Chem 1991;266:14064-71.
41. Lindner V, Reidy MA. Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc Natl Acad Sci U S A 1991;88:3739-43.
42. Morozov KM, Abalmasov KG, Serov RA, Krylova RG. Morphological changes in femoral vein wall structure in presence of persistent vertical reflux. Vestn Ross Akad Med Nauk 2005;4:81-5. (In Russian.)
43. Takase S, Pascarella L, Bergan JJ, Schmid-Schönbein GW. Hypertension-induced venous valve remodeling. J Vasc Surg 2004;39:1329-34.
44. Takase S, Pascarella L, Lerond L, Bergan JJ, Schmid-Schönbein GW. Venous hypertension, inflammation and valve remodeling. Eur J Vasc Endovasc Surg 2004; 28:484-93.
45. Pascarella L, Schmid-Schönbein GW, Bergan J. An animal model of venous hypertension: the role of inflammation in venous valve failure. J Vasc Surg 2005;41: 303-11.
46. Takase S, Lerond L, Bergan JJ, Schmid-Schönbein GW. The inflammatory reaction during venous hypertension in the rat. Microcirculation 2000;7:41-52.
47. Idem. Enhancement of reperfusion injury by elevation of microvascular pressures. Am J Physiol Heart Circ Physiol 2002;282:H1387-H1394.
48. Qui Y, Quijano RC, Wang SK, Hwang NH. Fluid dynamics of venous valve closure. Ann Biomed Eng 1995;23:750-9.
49. Lurie F, Kistner RL, Eklof B, Kessler D. Mechanism of venous valve closure and role of the valve in circulation: a new concept. J Vasc Surg 2003;38:955-61.
50. Traub O, Berk BC. Laminar shear stress: mechanisms by which endothelial cells transduce an atheroprotective force. Arterioscler Thromb Vasc Biol 1998;18: 677-85.
51. Yoshizumi M, Abe J, Tsuchiya K, Berk BC, Tamaki T. Stress and vascular responses: atheroprotective effect of laminar fluid shear stress in endothelial cells: possible role of mitogen-activated protein kinases. J Pharmacol Sci 2003;91:172-6.
52. Ohura N, Yamamoto K, Ichioka S, et al. Global analysis of shear stress-responsive genes in vascular endothelial cells. J Atheroscler Thromb 2003;10:304-13.
53. Berk BC, Abe JI, Min W, Surapisitchat J, Yan C. Endothelial atheroprotective and anti-inflammatory mechanisms. Ann N Y Acad Sci 2001;947:93-109.
54. Passerini AG, Milsted A, Rittgers SE. Shear stress magnitude and directionality modulate growth factor gene expression in preconditioned vascular endothelial cells. J Vasc Surg 2003;37:182-90.
55. Sorescu GP, Sykes M, Weiss D, et al. Bone morphogenic protein 4 produced in endothelial cells by oscillatory shear stress stimulates an inflammatory response. J Biol Chem 2003;278:31128-35.
56. Asakura T, Karino T. Flow patterns and spatial distribution of atherosclerotic lesions in human coronary arteries. Circ Res 1990;66:1045-66.
57. Moore JE Jr, Xu C, Glagov S, Zarins CK, Ku DN. Fluid wall shear stress measurements in a model of the human abdominal aorta: oscillatory behavior and relationship to atherosclerosis. Atherosclerosis 1994;110: 225-40.
58. Moazzam F, DeLano FA, Zweifach BW, SchmidSchönbein GW. The leukocyte response to fluid stress. Proc Natl Acad Sci U S A 1997;94:5338-43.
59. Fukuda S, Schmid-Schönbein GW. Regulation of CD18 expression on neutrophils in response to fluid shear stress. Proc Natl Acad Sci U S A 2003;100:13152-7.
60. Fukuda S, Yasu T, Predescu DN, Schmid-Schönbein GW. Mechanisms for regulation of fluid shear stress response in circulating leukocytes. Circ Res 2000; 86:E13-E18.
61. Secomb TW, Hsu R, Pries AR. Effect of the endothelial surface layer on transmission of fluid shear stress to endothelial cells. Biorheology 2001;38:143-50.
62. Zhao Y, Chien S, Weinbaum S. Dynamic contact forces on leukocyte microvilli and their penetration of the endothelial glycocalyx. Biophys J 2001;80:1124-40.
63. Mulivor AW, Lipowsky HH. Role of the glycocalyx in leukocyte-endothelial cell adhesion. Am J Physiol Heart Circ Physiol 2002;283:H1282-H1291.
64. Idem. Inflammation- and ischemia-induced shedding of venular glycocalyx. Am J Physiol Heart Circ Physiol 2004;286:H1672-H1680.
65. Payne SP, London NJ, Newland CJ, Thrush AJ, Barrie WW, Bell PR. Ambulatory venous pressure: correlation with skin condition and role in identifying surgically correctible disease. Eur J Vasc Endovasc Surg 1996;11:195-200.
66. Nicolaides AN, Hussein MK, Szendro G, Christopoulos D, Vasdekis S, Clarke H. The relation of venous ulceration with ambulatory venous pressure measurements. J Vasc Surg 1993;17:414-9.
67. Burnand KG, Whimster I, Naidoo A, Browse NL. Pericapillary fibrin in the ulcer-bearing skin of the leg: the cause of lipodermatosclerosis and venous ulceration. Br Med J (Clin Res Ed) 1982;285:1071-2.
68. Moyses C, Cederholm-Williams SA, Michel CC. Haemoconcentration and accumulation of white cells in the feet during venous stasis. Int J Microcirc Clin Exp 1987;5:311-20.
69. Thomas PR, Nash GB, Dormandy JA. White cell accumulation in dependent legs of patients with venous hypertension: a possible mechanism for trophic changes in the skin. Br Med J (Clin Res Ed) 1988; 296: 1693-5.
70. Wilkinson LS, Bunker C, Edwards JC, Scurr JH, Smith PD. Leukocytes: their role in the etiopathogenesis of skin damage in venous disease. J Vasc Surg 1993;17:669-75.
71. Pappas PJ, DeFouw DO, Venezio LM, et al. Morphometric assessment of the dermal microcirculation in patients with chronic venous insufficiency. J Vasc Surg 1997;26:784-95.
72. Lalka SG, Unthank JL, Nixon JC. Elevated cutaneous leukocyte concentration in a rodent model of acute venous hypertension. J Surg Res 1998;74:59-63.
73. Hahn TL, Unthank JL, Lalka SG. Increased hindlimb leukocyte concentration in a chronic rodent model of venous hypertension. J Surg Res 1999;81:38-41.
74. Yong K, Khwaja A. Leukocyte cellular adhesion molecules. Blood Rev 1990;4:211-25.
75. Saharay M, Shields DA, Porter JB, Scurr JH, Coleridge Smith PD. Leukocyte activity in the microcirculation of the leg in patients with chronic venous disease. J Vasc Surg 1997;26:265-73.
76. Saharay M, Shields DA, Georgiannos SN, Porter JB, Scurr JH, Coleridge Smith PD. Endothelial activation in patients with chronic venous disease. Eur J Vasc Endovasc Surg 1998;15:342-9.
77. Takase S, Schmid-Schönbein G, Bergan JJ. Leukocyte activation in patients with venous insufficiency. J Vasc Surg 1999;30:148-56.
78. Herouy Y, May AE, Pornschlegel G, et al. Lipodermatosclerosis is characterized by elevated expression and activation of matrix metalloproteinases: implications for venous ulcer formation. J Invest Dermatol 1998;111: 822-7.
79. Norgauer J, Hildenbrand T, Idzko M, et al. Elevated expression of extracellular matrix metalloproteinase inducer (CD147) and membrane-type matrix metalloproteinases in venous leg ulcers. Br J Dermatol 2002;147:1180-6.
80. Mwaura B, Mahendran B, Hynes N, et al. The impact of differential expression of extracellular matrix metalloproteinase inducer, matrix metalloproteinase-2, tissue inhibitor of matrix metalloproteinase-2 and PDGF-AA on the chronicity of venous leg ulcers. Eur J Vasc Endovasc Surg 2006; 31:306-10.
81. Burnand KG, Whimster I, Clemenson G, Thomas ML, Browse NL. The relationship between the number of capillaries in the skin of the venous ulcer-bearing area of the lower leg and the fall in foot vein pressure during exercise. Br J Surg 1981; 68:297-300.
82. Junger M, Hahn U, Bort S, Klyscz T, Hahn M, Rassner G. Significance of cutaneous microangiopathy for the pathogenesis of dermatitis in venous congestion due to chronic venous insufficiency. Wien Med Wochenschr 1994;144:206-10. (In German.)
83. Bates DO, Curry FE. Vascular endothelial growth factor increases hydraulic conductivity of isolated perfused micro-vessels. Am J Physiol 1996;271:H2520-H2528.
84. Shoab SS, Scurr JH, Coleridge-Smith PD. Increased plasma vascular endothelial growth factor among patients with chronic venous disease. J Vasc Surg 1998;28:535-40.
85. Idem. Plasma VEGF as a marker of therapy in patients with chronic venous disease treated with oral micronised flavonoid fraction - a pilot study. Eur J Vasc Endovasc Surg 1999;18:334-8.
86. 1 gene expression and protein production. J Vasc Surg 1999;30:1129-45.
87. Sansilvestri-Morel P, Rupin A, Jaisson S, Fabiani J-N, Verbeuren TJ, Vanhoutte PM. Synthesis of collagen is dysregulated in cultured fibroblasts derived from skin of subjects with varicose veins as it is in venous smooth muscle cells. Circulation 2002;106:479-83.
88. Ackerman Z, Seidenbaum M, Loewenthal E, Rubinow A. Overload of iron in the skin of patients with varicose ulcers: possible contributing role of iron accumulation in progression of the disease. Arch Dermatol 1988;124:1376-8.
89. Yeoh-Ellerton S, Stacey MC. Iron and 8-isoprostane levels in acute and chronic wounds. J Invest Dermatol 2003;121:918-25.
90. Wenk J, Foitzik A, Achterberg V, et al. Selective pick-up of increased iron by defe-roxamine-coupled cellulose abrogates the iron-driven induction of matrix-degrading metalloproteinase-1 and lipid peroxidation in human dermal fibroblasts in vitro: a new dressing concept. J Invest Dermatol 2001;116:833-9.
91. Zamboni P, Tognazzo S, Izzo M, et al. Hemochromatosis C282Y gene mutation increases the risk of venous leg ulceration. J Vasc Surg 2005;42:309-14.
92. Ibegbuna V, Delis KT, Nicolaides AN, Aina O. Effect of elastic compression stockings on venous hemodynamics during walking. J Vasc Surg 2003;37:420-5.
93. Motykie GD, Caprini JA, Arcelus JI, Reyna JJ, Overom E, Mokhtee D. Evaluation of therapeutic compression stockings in the treatment of chronic venous insufficiency. Dermatol Surg 1999;25:116-20.
94. Andreozzi GM, Cordova R, Scomparin MA, Martini R, D'Eri A, Andreozzi F. Effects of elastic stocking on quality of life of patients with chronic venous insufficiency: an Italian pilot study on Triveneto Region. Int Angiol 2005;24:325-9.
95. Barwell JR, Davies CE, Deacon J, et al. Comparison of surgery and compression with compression alone in chronic venous ulceration (ESCHAR study): randomised controlled trial. Lancet 2004;363:1854-9.
96. Tenbrook JA Jr, Iafrati MD, O'Donnell TF Jr, et al. Systematic review of outcomes after surgical management of venous disease incorporating subfascial endoscopic perforator surgery. J Vasc Surg 2004;39: 583-9.
97. Boisseau MR. Pharmacologie des médicaments veinotoniques: données actuelles sur leur mode d'action et les cibles thérapeutiques. Angeiologie 2000;52:71-7.
98. Eberhardt RT, Raffetto JD. Chronic venous insufficiency. Circulation 2005;111: 2398-409.
99. Takase S, Delano FA, Lerond L, Bergan JJ, Schmid-Schönbein GW. Inflammation in chronic venous insufficiency: is the problem insurmountable? J Vasc Res 1999; 36:Suppl 1:3-10.
100. Nicolaides AN. From symptoms to leg edema: efficacy of Daflon 500 mg. Angiology 2003;54:Suppl 1:S33-S44.